Axsome Therapeutics (NASDAQ: AXSM) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Axsome Therapeutics to related businesses based on the strength of its profitability, institutional ownership, dividends, valuation, analyst recommendations, risk and earnings.
Insider & Institutional Ownership
23.6% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 35.2% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of current recommendations for Axsome Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Axsome Therapeutics Competitors||893||3287||11783||235||2.70|
Axsome Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 248.21%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.14%. Given Axsome Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than its peers.
Risk & Volatility
Axsome Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Axsome Therapeutics’ peers have a beta of 5.98, meaning that their average stock price is 498% more volatile than the S&P 500.
Valuation & Earnings
This table compares Axsome Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Axsome Therapeutics||N/A||-$27.20 million||-4.12|
|Axsome Therapeutics Competitors||$284.49 million||$34.10 million||69.75|
Axsome Therapeutics’ peers have higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Axsome Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axsome Therapeutics Competitors||-5,145.19%||-170.27%||-35.98%|
Axsome Therapeutics peers beat Axsome Therapeutics on 7 of the 13 factors compared.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.